<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9136">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05704582</url>
  </required_header>
  <id_info>
    <org_study_id>MP-12-2023-3234</org_study_id>
    <nct_id>NCT05704582</nct_id>
  </id_info>
  <brief_title>RCT Comparing Avatar Intervention to Supportive Intervention to Reduce Cannabis Use in Patients With Psychotic Disorders</brief_title>
  <acronym>AC2</acronym>
  <official_title>A Randomized Controlled Trial Comparing Avatar Intervention to an Addiction Supportive Intervention to Reduce Cannabis Use in Patients With Psychotic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ciusss de L'Est de l'Île de Montréal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ciusss de L'Est de l'Île de Montréal</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to conduct a single-blind randomized controlled trial to&#xD;
      verify whether the Avatar Intervention has greater efficacy over supportive intervention to&#xD;
      reduce cannabis use in patients with psychotic disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psychotic disorders (PD) are characterized by a loss of contact with reality. Cannabis use is&#xD;
      one of the key factors leading to psychiatric re-hospitalization in PD. In these populations,&#xD;
      cannabis use is also associated with depressive symptoms, medication non-compliance,&#xD;
      hostility as well as reduced quality of life. Unfortunately, there is no evidence-based&#xD;
      intervention available for the treatment of cannabis use disorder (CUD) in this population.&#xD;
      Novel interventions for CUD are thus critically needed. Virtual reality-based therapies are a&#xD;
      promising avenue that allow patients to try novel strategies in real time instead of having&#xD;
      to learn abstract rules. To fill a clinical need, the investigators have created a&#xD;
      distinctive intervention for CUD in patients with PD. The Avatar Intervention displays strong&#xD;
      experiential and relational components that are crucially missing in conventional&#xD;
      interventions.&#xD;
&#xD;
      Hence, the primary outcomes are reductions in cannabis use, cannabis use disorder severity,&#xD;
      and increased quality of life. The investigators will also explore whether the greater&#xD;
      improvements attributable to the Avatar Intervention persist in time, and perform analyses on&#xD;
      sex/gender, motivation to change cannabis habits, psychotic relapses, and THC metabolite&#xD;
      levels.&#xD;
&#xD;
      Noteworthily, cannabis-related hospitalizations have been identified as one of the core&#xD;
      indicators to measure the success of cannabis legalization. As a result, there is a pressing&#xD;
      need to design innovative interventions that could have a significant impact on this costly&#xD;
      and prime outcome. As there is no evidence-based therapeutic options for CUD in patients with&#xD;
      PD, the current trial will contribute to the validation of a novel approach and create new&#xD;
      therapeutic possibilities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2023</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">January 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-blind randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cannabis use (Timeline Follow-Back)</measure>
    <time_frame>Within 1 week before treatment, within 1 week after treatment, follow-ups at 3 months, 6 months and 12 months</time_frame>
    <description>A standardized tool consisting of asking the patients how many joints they smoked each day of the week during the past week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the severity of the cannabis use disorder (Cannabis Use Problems Identification Test - CUPIT)</measure>
    <time_frame>Within 1 week before treatment, within 1 week after treatment, follow-ups at 3 months, 6 months and 12 months</time_frame>
    <description>16-item self-reported questionnaire assessing cannabis use and dependence; Range 3-82, higher values indicating a more severe cannabis use disorder</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life(Quality of Life Enjoyment and Satisfaction Questionnaire - QLESQ-SF &amp; Quality of Life Scale - QLS)</measure>
    <time_frame>Within 1 week before treatment, within 1 week after treatment, follow-ups at 3 months, 6 months and 12 months</time_frame>
    <description>QLESQ-SF: 16-item self-reported scale measuring enjoyment and satisfaction experienced during the past week in various areas of daily functioning; Range 14-70, Higher values indicate a better satisfaction of life&#xD;
QLS: 21-item scale based on a semistructured interview designed to assess deficit symptoms; Range 0-126, higher values indicate a better quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Psychotic Disorders</condition>
  <condition>Cannabis Use Disorder</condition>
  <condition>Mental Health Disorder</condition>
  <arm_group>
    <arm_group_label>Avatar Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Avatar Intervention will take place over 8 consecutive weeks, with one session per week. Additional sessions (up to a maximum of 4 sessions) will be offered if needed. Each session will last approximately 60 minutes. The goal of the intervention will be to help you reduce cravings related to your cannabis use with the use of virtual reality and avatars.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Addiction supportive intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Addiction supportive intervention will take place over 8 consecutive weeks, with one session per week. Additional sessions (up to a maximum of 4 sessions) will be offered if needed. Each session will last approximately 60 minutes. The goal of the intervention will be to help you reduce cravings related to your cannabis use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Avatar Intervention</intervention_name>
    <description>8 weekly sessions of 60 minutes. Possibility of 4 additional sessions.</description>
    <arm_group_label>Avatar Intervention</arm_group_label>
    <other_name>Avatar-CUD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Addiction supportive intervention</intervention_name>
    <description>8 weekly sessions of 60 minutes. Possibility of 4 additional sessions.</description>
    <arm_group_label>Addiction supportive intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females over 18 years of age who meet the DSM-5 criteria for CUD (≥4&#xD;
             criteria) ;&#xD;
&#xD;
          -  Patients will meet the DSM-5 criteria for schizophrenia, schizoaffective disorder, or&#xD;
             bipolar disorder with psychotic symptoms. Diagnoses will be established with the&#xD;
             Structured Interview for DSM-5 (SCID-5).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current SUD for a substance other than cannabis ;&#xD;
&#xD;
          -  Ongoing pharmacological or psychological treatment for CUD ;&#xD;
&#xD;
          -  Ongoing detoxification for cannabis withdrawal ;&#xD;
&#xD;
          -  Presence of neurological disorders ;&#xD;
&#xD;
          -  Presence of a severe and unstable physical illness ;&#xD;
&#xD;
          -  Inability to provide consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Dumais, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Montreal, Institut universitaire en santé mentale de Montréal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephane Potvin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Montreal, Institut universitaire en santé mentale de Montréal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuel Stip, MD, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>United Arab Emirates University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amal Abdel Baki, MD, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>University of Montreal, Centre hospitalier de l'Université de Montréal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert-Paul Juster, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Montreal, Institut universitaire en santé mentale de Montréal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Hélène Goulet, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Montreal, Institut universitaire en santé mentale de Montréal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luigi De Benedictis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut universitaire en santé mentale de Montréal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre Dumais, MD, PhD</last_name>
    <phone>514-251-4000</phone>
    <phone_ext>3212</phone_ext>
    <email>contact@avatar-intervention.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research center of the Institut universitaire en santé mentale de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Dumais, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Alexandre Dumais, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephane Potvin, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>January 20, 2023</study_first_submitted>
  <study_first_submitted_qc>January 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2023</study_first_posted>
  <last_update_submitted>February 24, 2023</last_update_submitted>
  <last_update_submitted_qc>February 24, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cannabis</keyword>
  <keyword>virtual reality intervention</keyword>
  <keyword>psychotic disorders</keyword>
  <keyword>substance use disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

